Isolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite

Similar documents
Why change is inevitable in aseptic manufacturing?

Current Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)

EU GMP ANNEX 1 CHANGES CLARIFICATION AND IMPACT

Overview and Introduction Annex 1 Revision

PDA: A Global. Association. Contamination Control: Particles, Bio-contamination, Aseptic manufacturing. PDA Parenteral 2014 Munich Conference

Environmental Monitoring of Aseptic Processing Areas - 1

Trends in Sterile Manufacturing Technologies

INSPECTOR S OBSERVATIONS AND WARNING LETTER

While the global pharmaceutical industry tends to be conservative

PDA: A Global Association

FDA s Guidance for Industry

INTEGRATED VPHP DECONTAMINATION SYSTEMS THE EMERGING UTILITY

Containment Why and How to evaluate

Webinar. The New EU-GMP Annex 1 draft Dupont. GOP-Innovations your Partner for Practical Training and e-learning. 8 June 2018

PDA: A Global. Association Dr. Friedrich Haefele Boehringer Ingelheim Pharma GmbH & Co. KG. Maturing Aseptic Technologies

LUNCH AND LEARN. September 11, CE Activity Information & Accreditation

Introduction and Background

GETINGE ISOFLEX MULTI-PURPOSE ISOLATOR

Gloveless Robotic Technologies in Aseptic. Personalized Cytotoxic. Association. Drugs. Sergio Mauri FEDEGARI GROUP

Overview of Inspection Issues with Legacy Products. Barbara Breithaupt Consumer Safety Officer

Compounding Aseptic Isolators (CAI) James T Wagner

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

On-Site GMP Training GMP COMPLIANCE TECHNICAL

MONZA ST5 Project. Alberto Penati Patheon Monza EU Engineering Director. The world leader in serving science

Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC

HVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction

Complaints Investigations Root Cause Analysis

Microbiological Consideration for Non-Sterile Pharmaceutical

EU GMP ANNEX 1 DRAFT CLARIFICATION AND IMPACT

T H E P R O P O S A L F O R T H E Y E A R

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Aseptic Processing Practices and Process Validation of Aseptic Operators

HISTORY AND MILESTONES

Baxa Corporation. Technical Paper. Environmental Controls for Sterile Compounding

MINIMUM REQUIREMENTS FOR A VENDOR

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

An Introduction to Double Dragon Consulting

Aseptic Fill / Finish Facility Design for Compliance

VALIDATION AS A KEY TOOL IN SUCCESSFUL TRANSFER OR ESTABLISHMENT OF A MEDICAL DEVICE COMPANY IN A NEW FACILITY

Understanding expectations for validation of unidirectional air flow studies smoke studies

Supplementary Training Modules on Good Manufacturing Practice. Validation. WHO Technical Report Series, No. 937, Annex 4.

Design Considerations for TGA Licensed Pharmacies. Presented by Ashley Isbel 11 th August 2015

How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

Environmental Control Requirements. Gordon Farquharson July 2017

Overview of a sterility assurance program for PET drugs

FLEXIBLE CONTAINMENT

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Animal Facility Biosafety Level 3 Checklist (date: April 16, 1998)

+ IQ/OQ Protocol Installation Qualification/ Operation Qualification

SCHOTT Pharmaceutical Systems. adaptiq - ready-to-use vials for aseptic processing

Contents. Contents (13) 1 Production (23)

Biological contamination events in isolators: What lessons can be learned?

Annex 1 to the Good manufacturing practices guide Manufacture of sterile drugs GUI-0119

Technical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities

On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).

For sterile products manufacturing, Lyoseal is an innovative technology. presented by Mr. Tony Bouzerar from BioCorp offers us detailed

Guidance for Industry

CONTAINED ASEPTIC TRANSFER VALVES

GOOD MANUFACTURING PRACTICE

PERFORMANCE QUALIFICATION PROTOCOL HVAC SYSTEM

Sterile Manufacturing

ISPE Aseptic Conference February 2014 Washington, D.C.

Review Validation of aseptic processes for pharmaceuticals

Pharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD

A Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime

Environmental Monitoring of Aseptic Processing Areas - 2

PI s Name Date Bldg./Rm#

Appendix B PROCEDURES FOR REMOVAL OF MOULD-CONTAMINATED MATERIALS

MASTER PLANNING FOR VALIDATION

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

Packaging Operations Technical Subcommittee

FZ LABORATORY SERVICES

Presentation Title Author Name

Microbial contamination is a

Validation Master Plan

National Institutes of Health (NIH) Office of Science Policy (OSP) Recombinant or

Production and Test Facilities Via Romagnoli, Fiorenzuola d Arda (PC) - Italy - Tel Fax Containment Systems

WARNING LETTER CMS #

Aseptic vial filling line

Introducing an Innovative, Advanced Aseptic Filling Technology to a New Manufacturing Facility. Dr. Aidan Harrington DPS Engineering

Emcure Pharmaceuticals Limited 3/3/16

FLORIDA SOCIETY OF HEALTH SYSTEM PHARMACISTS NOVEMBER 4, 2016 JAMES T WAGNER CONTROLLED ENVIRONMENT CONSULTING

Quality & Regulatory Issues in Biopharmaceutical Facility Design A Perspective from Industry Trends

Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations

Inspection Checklist for NIH BL3 Laboratories (7 CFR 331; 9 CFR 121; 42 CFR 73; NIH Guidelines)

ANNEX 1: COMMENT SUBMISSION DOCUMENT

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union


Points to Consider for Aseptic Processing Part 2 May 2016

AseptiSafe CONTAINED ASEPTIC TRANSFER VALVES. Handling sensitive ingredients and components in aseptic processing

Validation Study on How to Avoid Microbial Contamination during Pharmaceutical Production

Section 6.6 BSL3 & ABSL3 Biocontainment

Guidance for Industry Sterile Drug Products Produced by Aseptic Processing Current Good Manufacturing Practice

C. Ventilation Considerations for Biosafety Level 2 Laboratories 3-2. D. Biological Safety Cabinets and Other Containment Considerations 3-3

arrier Isolation Technology

Material Transfer Solutions. Scott Lodge Technical Sales Manager Biodecon Solutions

A risk based approach to managing environmental excursions

Porton Biopharma Limited 1/17/17

Sterility Test Isolators

Transcription:

APV 2008 Basle Conference Basle, Switzerland: May 28 & 29 2008 Isolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite John R. Chester Principal Engineer Global Pharmaceutical Supply Group (J&J) Raritan, NJ USA 908-927 927-3966 Credit Developed in concert with Les Edwards (CEO Isogen) for ISPE

Outline Isolator Systems and RABS Key notes from the Sept 2005 FDA Guidance RABS Definitions ISPE / FDA Position Paper Key Benefits and Limitations Facility Approach Analysis Capital Savings with RABS Facility Cost Comparison (Iso( vs. RABS) on Vial Fill/Lyo Line Facility Layout Issues Syringe RABS Line Total Facility Cost Comparison Iso vs. RABS Conclusions

Key Advantages of Isolators noted in the FDA Guidance Doc Minimize the extent of personnel involvement Separates the external cleanroom environment from the aseptic processing line. Emphasizes that the isolator must be Well designed Supported by adequate procedures Properly monitored Properly controlled Provides warning that should not adopt a false sense of security Also acknowledges need to establish new procedures addressing issues unique to isolator systems. All of the above also apply to RABS

Summary of FDA Guidance on Isolators Appendix acknowledges the advantages of isolation technology, but warns that vigilance with good aseptic technique and procedures is still critical. Human interventions represent significant risks, especially glove interventions. This is mentioned repeatedly. Use glove integrity testing, microbial monitoring, under-gloves, sanitization, and sterile tools to minimize risk of personnel contaminating the enclosed aseptic process. If a material can be steam sterilized, then it should be. Background classification of 100,000 (ISO 8) and interior Class 100 (ISO 5). *Does not apply to RABS

Restricted Access Barrier Systems (RABS) Barrier is a generic term Flexible curtains Rigid polycarbonate or glass enclosures (limited access barriers - LABS) Rigid enclosure w/ gloves, RTPs, half-suits, automation (restricted access barrier system RABS) Basic Design Principles Unidirectional HVAC system to provide Class 100 / ISO 5 / Grade A environment. Transfer systems (such as RTPs, UV, ebeam, etc ) High-level disinfection of all interior surfaces (sporicidal) before batch manufacture (or after open door intervention) Surrounding room ISO 7 (Grade B) minimum

Restricted Access Barrier Systems (RABS) More Controversial Design Principles (from the ISPE/FDA RABS Position Paper) If you decide to open the door (still considered RABS, but actually LABS in my book) Door opening considered a significant event! Disinfection after intervention (therefore, full line clearance) Interlocked door access with recorded intervention alarms and line clearance. Positive pressure (positive airflow) from inside to outside the barrier this is tougher than it sounds Additional ISO 5 space SURROUNDING the RABS for open door intervention protection (under the door swing)

The driving reasons for RABS Primary reduction in capital equipment costs RABS are typically less complex and cheaper than isolators Typically no automated disinfection system (H 2 O 2 or others) But, significant impact of facility HVAC costs must be included in the evaluation. Surrounding room must be Grade B/ISO 7 (instead of C or D) some area possibly must be Grade A/ISO 5 for door swing Increased costs of gowning, including gowning materials and productivity losses Additional airlocks increases square footage of suite Increased environmental monitoring for surrounding A and B areas

The driving reasons for RABS Secondary perceived reduction in validation costs and schedule But, no automated disinfection system (H2O2 or others) Must still provide data on a non-automated high-level disinfection method of all interior surfaces (sporicidal) Must still provide residue effects and disinfectant removal data But, increased environmental qualification and monitoring costs for Grade A/B versus C/D area. But, same costs for transfer systems validation versus an isolator (such as RTPs, UV, ebeam, etc )

Case Study #1: Iso vs. RABS Integrated Vial Fill/Lyo Line Integrated Filling/Lyo/Loading 250 vial/min filler (2-20mL) 20mL) 3x25m 2 lyophilizers TCAR-based lyo loading system Initial Design: Fully Isolated System Re-design: Utilize RABS for perceived increased flexibility for modified product mix Results Layouts (subsection of facility) Capital Cost Comparison Operating Cost Comparison

Initial Layout Area Sq. Ft. 270 2820 with Isolators Sq. Ft. 270 2820 A B 0 C

Redesigned Area A B C w/ RABS Sq. Ft. 418 2972 340

Current Area Layout Sq. Ft. 906 2583 340 A B C

Cost Analysis Initial Capital Case #1 Est. Cost per Sq. Ft. Iso Area Iso Cost RABS Area RABS Cost Capital Costs - Equipment $ 4,750,000 $ 2,850,000 A/ISO 5 Area $ 900 270 $ 243,000 906 $ 815,400 B/ISO 7 Area $ 700 0 $ - 2583 $ 1,808,100 C/ISO 8 Area $ 500 2820 $ 1,410,000 340 $ 170,000 Airlock / Gowning Area $ 600 400 $ 240,000 1000 $ 600,000 Total Estimate 3490 $ 6,643,000 4829 $ 6,243,500 Net Savings $ 399,500

Cost Analysis Initial Capital Case #1 Isolator Facility Capital Equipment Cost Initial cost savings expected to be > $2 Million Base cost savings appears to be < $500K Additional costs Grade A space expansion and air return handling ($>100K + design fees) Uncertainty in RABS regulatory response (chose conservative approach) Net Result: Re-design from iso to RABS saved little capital cost. Additional flexibility driver was reduced w/ increased production steps and floor plan changes.

Case Study #2: RABS Syringe Filling Line Restricted Access Barrier Syringe Fill Line 300 Syringe/min filler (B-D Hypak Tubs) Manual tub disinfection upon entry Conventional facility layout Results Tub Entry and Handling Layouts Component Prep / Handling Areas Filling Room Layout

Tub Handling and Entry Layouts 1 1 1 2 1 0 9 4 8 7 6 5 Tub Transfer Flow Unclassified (1194) Grade D Grade C Grade B Grade A Grade B Grade C Grade D Unclassified (1185) RABS Layout Area ft 2 A 20 B 100 C+ 870 3 Isolator Layout 2 1 Area ft 2 A 20 B 0 C+ 970

Syringe Line: Filling Room Layout RABS Layout Area ft 2 A 330 B 510 C+ N/A Isolator Layout Area ft 2 A 110 B 0 C+ 730

Syringe Line: Other Area Layouts Component Prep Washing Pass-through Autoclaves and Sterile Staging Change Parts Clean Storage Airlocks Grade B Corridor RABS Layout Area ft 2 A 150 Isolator Layout Area ft 2 A 150 B 800 B N/A C+ 1500 C+ 2300

Cost Analysis Initial Capital Case #2 Est. Cost per Sq. Ft. Iso Area Iso Cost RABS Area RABS Cost Capital Costs - Equipment $ 1,500,000 $ 750,000 A/ISO 5 Area $ 900 170 $ 153,000 500 $ 450,000 B/ISO 7 Area $ 700 0 $ - 1460 $ 1,022,000 C/ISO 8 Area $ 500 4000 $ 2,000,000 2320 $ 1,160,000 Total Estimate 4170 $ 3,653,000 4280 $ 3,382,000 Net Savings $ 271,000

Cost Analysis Initial Capital Case #2 Isolator Facility Capital Equipment Cost Initial cost savings expected to be > $1.5 Million Base cost savings appears to be approx. $250K Additional costs Grade A space expansion and air return handling ($>100K + design fees) Net Result: Design from iso to RABS saved little capital cost.

Additional Cost Analysis Applies to either Case #1 or #2 Validation Equipment IQ/OQ Equipment PQ Facility Qualification Operating Expenses Gowning Productivity Changeover Process Utilities Maintenance Revalidation Environmental Monitoring Facility Equipment / Isolators

Cost Analysis - Validation Equipment Qualification (RABS Cost Savings - $50-$75 $75 K) Isolator and Gassing System IQ/OQ: 4-64 6 weeks RABS IQ/OQ: 2-42 4 weeks Performance Qualification (RABS Cost Savings - $80-$150K) $150K) Isolator Gassing PQ - 12 weeks RABS Manual Disinfection Process PQs 8 weeks Facility Qualification (RABS Cost Increase $75-100K) Increased Grade A Space More HEPA certifications More viable air, particulate, and surface monitoring Net Validation Savings w/ RABS = approx $100K and 2-42 weeks (critical path)

Cost Analysis Operating Expenses Gowning Higher level gowning in RABS B space (5 people, 4 changes per day, 5 days per week, 40 weeks per year x $75 per gown = $300K/year) conservative (single shift - does not include supervisory, cleaning crews, monitoring personnel, other support) Summary: RABS costs >$300K more per year Productivity Higher level gowning w/ RABS time to enter/leave More airlocks w/ RABS Increased cleaning and monitoring w/ RABS, including manual decontamination vs. automated H2O2 gassing. Personnel comfort, motivation improved w/ isolators Summary : RABS reduced productivity

Cost Analysis Operating Expenses Changeover Process Perception that flexibility comes w/ RABS, but very similar steps required, some more restrictive. Set-up and cleaning of isolator can be done fully open, then close and gas automatically (less manpower intensive). Glove testing/set-up similar w/ RABS and isolator Set-up and cleaning of RABS can be done fully open, then manual disinfection process must begin w/ doors open is specific order, ending w/ glove disinfection w/ closed doors. Difficult handling for aseptic placement of stopper bowl and other autoclaved components. Summary: RABS increased changeover process time

Cost Analysis Operating Expenses Utilities RABS requires more power to run larger HVAC units Maintenance PMs on Equip vs. HVAC may be similar Increased HEPA certifications (more in RABS facility) Glove Testing and Replacement (similar on both) Annual Revalidation H2O2 Gassing typical 3-53 5 days (cost $20-30K) Manual process potentially less revalidation testing.

Cost Analysis Operating Expenses (Environmental Monitoring) Sample Freq Iso Samples Iso Annual Cost RABS Samples RABS Annual Cost Grade A Area continuous/ per run 12 air, 40 surface $1,040,000 18 air, 60 surface $1,560,000 Grade B Area per run / daily 0 $ - 8 air, 40 surface $ 960,000 Grade C Area weekly 12 air, 80 surface $368,000 7 air, 40 surface $188,000 Total Estimate $1,408,000 $2,708,000 Net Cost w/ RABS **($1,300,000) *Cost Basis = $100/sample. Operation 5 days/week @ 40 weeks/year **Represents an cost INCREASE w/ RABS, not savings.

Cost Analysis Summary Item Iso RABS Comments Initial Capital RABS Saves $1.5-$2 $2 Million Barrier Equipment Initial Capital - Facility RABS Costs >$1.2-1.5Million 1.5Million Validation RABS Saves $100K and 2-42 4 weeks Operating Costs: Gowning RABS Gowning Cost >$300K/yr Productivity RABS reduced productivity Changeover RABS increased changeover time Utilities RABS increased utility cost Maintenance similar Annual Reval RABS slightly lower cost Env.. Monitoring RABS EM Cost >$1.3 Million

Conclusions RABS may be considered an attractive solution for retrofits of existing lines, but will not replace isolation technology. Isolators and RABS will evolve as a pieces of process equipment in and of themselves, with a defined set of functions and requirements. RABS utilizes some of the advantages of isolation technology, not all of them. With the drive toward improved technology and better solutions for aseptic processing, many RABS stand far short of the capabilities of isolation technology and will likely be used in the future for only specific/narrow applications.